Let me take a minute to talk about financial values. As you may have seen in our earnings release this afternoon, this is the first quarter in which we are providing guidance for investors. In the first half of 2013, we achieved growth in product revenue of 87% as measured by the product revenues for the same period in 2012. We expect to see a similar growth rate in our product revenues in the third quarter of 2013 compared with the third quarter of 2012.
In the fourth quarter of 2013, we expect an increase in that growth rate as measured against our product revenue in the fourth quarter of 2012. We expect this acceleration in our growth rate in Q4 as we believe our current investment in sales and marketing capabilities will begin to pay off. Based on these expected growth rates, we anticipate total product revenues for 2013 of $2.3 million to $2.7 million, which would equate to total revenues for 2013 of $3.2 million to $3.6 million.
Now, I want to point out that these are product revenues projected by the Company for 2013 do not include significant revenues from drug delivery procedures, as the drug therapies being delivered with ClearPoint are in clinical trials and have not received regulatory approval.